Switch theme
Sign up to access all valuation multiples
Prim SA is engaged in the provision of hospital supplies. The company is in a hospital and orthopedic supplies and materials for physiotherapy, thalassotherapy, thermal therapy, rehabilitation, geriatrics, as well as daily living aids. Prim work across a division of healthcare units such as Operating Theatres; Pain Management Centres; Plastic Surgery; Endosurgery and Cardiovascular.
1966
563
LTM Revenue $286M
LTM EBITDA $35.3M
$240M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Prim has a last 12-month revenue (LTM) of $286M and a last 12-month EBITDA of $35.3M.
In the most recent fiscal year, Prim achieved revenue of $275M and an EBITDA of $31.0M.
Prim expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Prim valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $286M | XXX | $275M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $131M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 48% | XXX | XXX | XXX |
| EBITDA | $35.3M | XXX | $31.0M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| EBIT | $22.2M | XXX | $16.5M | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $15.7M | XXX | $12.9M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $3.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 3, 2025, Prim's stock price is EUR 12 (or $14).
Prim has current market cap of EUR 197M (or $233M), and EV of EUR 203M (or $240M).
See Prim trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $240M | $233M | XXX | XXX | XXX | XXX | $0.95 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 3, 2025, Prim has market cap of $233M and EV of $240M.
Prim's trades at 0.9x EV/Revenue multiple, and 7.7x EV/EBITDA.
Equity research analysts estimate Prim's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Prim has a P/E ratio of 14.8x.
See valuation multiples for Prim and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $233M | XXX | $233M | XXX | XXX | XXX |
| EV (current) | $240M | XXX | $240M | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | 6.8x | XXX | 7.7x | XXX | XXX | XXX |
| EV/EBIT | 10.8x | XXX | 14.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 14.8x | XXX | 18.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 18.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPrim's last 12 month revenue growth is 8%
Prim's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Prim's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Prim's rule of X is 32% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Prim and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | 9% | XXX | XXX | XXX |
| Rule of 40 | 21% | XXX | 19% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 32% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Prim acquired XXX companies to date.
Last acquisition by Prim was XXXXXXXX, XXXXX XXXXX XXXXXX . Prim acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Prim founded? | Prim was founded in 1966. |
| Where is Prim headquartered? | Prim is headquartered in Spain. |
| How many employees does Prim have? | As of today, Prim has 563 employees. |
| Is Prim publicy listed? | Yes, Prim is a public company listed on MAD. |
| What is the stock symbol of Prim? | Prim trades under PRM ticker. |
| When did Prim go public? | Prim went public in 1997. |
| Who are competitors of Prim? | Similar companies to Prim include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Prim? | Prim's current market cap is $233M |
| What is the current revenue of Prim? | Prim's last 12 months revenue is $286M. |
| What is the current revenue growth of Prim? | Prim revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Prim? | Current revenue multiple of Prim is 0.8x. |
| Is Prim profitable? | Yes, Prim is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Prim? | Prim's last 12 months EBITDA is $35.3M. |
| What is Prim's EBITDA margin? | Prim's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of Prim? | Current EBITDA multiple of Prim is 6.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
